Skip to main content
. Author manuscript; available in PMC: 2015 Jan 6.
Published in final edited form as: Pediatr Blood Cancer. 2013 Oct 11;61(4):647–652. doi: 10.1002/pbc.24822

Fig. 2.

Fig. 2

Survivin-2B/ΔEx2 expression and clinical outcome. Event-free survival (A) and overall survival (B) for patients according to the 2B/ΔEx2 ratio. C: Relapse risk, according to the 2B/ΔEx2 ratio, calculated from the end of course 2 induction therapy.